[go: up one dir, main page]

UA83272C2 - Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну - Google Patents

Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну

Info

Publication number
UA83272C2
UA83272C2 UAA200607304A UAA200607304A UA83272C2 UA 83272 C2 UA83272 C2 UA 83272C2 UA A200607304 A UAA200607304 A UA A200607304A UA A200607304 A UAA200607304 A UA A200607304A UA 83272 C2 UA83272 C2 UA 83272C2
Authority
UA
Ukraine
Prior art keywords
flagellin
methods
protecting against
against radiation
radiation
Prior art date
Application number
UAA200607304A
Other languages
English (en)
Russian (ru)
Inventor
Андрей В. Гудков
Original Assignee
Клевеленд Клінік Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Клевеленд Клінік Фаундейшн filed Critical Клевеленд Клінік Фаундейшн
Publication of UA83272C2 publication Critical patent/UA83272C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)

Abstract

Винахід стосується способу захисту ссавця від ефектів іонізуючого випромінювання, який полягає у введенні ссавцю композиції, що містить флагелін.
UAA200607304A 2003-12-02 2004-12-02 Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну UA83272C2 (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52646103P 2003-12-02 2003-12-02
US52646003P 2003-12-02 2003-12-02
US52649603P 2003-12-02 2003-12-02
US52666603P 2003-12-02 2003-12-02
PCT/US2004/040753 WO2005056042A2 (en) 2003-12-02 2004-12-02 Methods of protecting against radiation using flagellin

Publications (1)

Publication Number Publication Date
UA83272C2 true UA83272C2 (uk) 2008-06-25

Family

ID=34682348

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200607304A UA83272C2 (uk) 2003-12-02 2004-12-02 Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну

Country Status (18)

Country Link
US (2) US11235028B2 (uk)
EP (1) EP1706133B1 (uk)
JP (1) JP4750716B2 (uk)
KR (1) KR101287905B1 (uk)
CN (1) CN1913915B (uk)
AT (1) ATE483467T1 (uk)
AU (1) AU2004296828B2 (uk)
CA (1) CA2547869C (uk)
DE (1) DE602004029500D1 (uk)
DK (1) DK1706133T3 (uk)
EA (1) EA010291B1 (uk)
IL (1) IL175974A (uk)
PL (1) PL1706133T3 (uk)
PT (1) PT1706133E (uk)
SG (2) SG148215A1 (uk)
SI (1) SI1706133T1 (uk)
UA (1) UA83272C2 (uk)
WO (3) WO2005056055A2 (uk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580321B2 (en) * 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
WO2006138238A2 (en) * 2005-06-13 2006-12-28 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
ES2412237T3 (es) 2008-08-01 2013-07-10 Cleveland Biolabs, Inc. Métodos para tratar lesiones por reperfusión
KR101254244B1 (ko) * 2010-11-01 2013-04-12 한국원자력의학원 ＴＧＦ－β１을 유효성분으로 함유하는 방사선 피폭 또는 조사에 의한 세포손상의 예방 또는 치료용 조성물
SG191830A1 (en) 2011-01-10 2013-08-30 Cleveland Biolabs Inc Use of toll-like receptor agonist for treating cancer
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
KR20150085146A (ko) * 2014-01-13 2015-07-23 한국원자력의학원 소포체 스트레스 저해제를 포함하는 방사선 방호용 조성물
ES2816630T3 (es) * 2014-07-30 2021-04-05 Genome Prot Inc Composiciones de flagelina y usos
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
KR101634380B1 (ko) 2015-06-23 2016-06-28 한국생산기술연구원 Tlr5 아고니스트 단백질의 생산방법
CN108368531B (zh) * 2015-12-16 2022-03-25 豪夫迈·罗氏有限公司 改进的重组产生方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN112203675A (zh) * 2018-04-24 2021-01-08 基因组保护股份有限公司 用于改善虚弱和衰老的方法
KR102524577B1 (ko) * 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
WO2022086190A1 (ko) * 2020-10-20 2022-04-28 주식회사 메디스팬 플라젤린 융합 단백질 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US20020009747A1 (en) * 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US7300749B2 (en) * 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) * 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US20030077262A1 (en) * 2001-10-02 2003-04-24 Guido Franzoso Methods and compositions for modulating apoptosis
US7078165B2 (en) * 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2007513183A (ja) 2007-05-24
SG176524A1 (en) 2011-12-29
WO2005056055A3 (en) 2006-05-18
ATE483467T1 (de) 2010-10-15
US20220105155A1 (en) 2022-04-07
SI1706133T1 (sl) 2011-02-28
AU2004296828B2 (en) 2011-07-07
CA2547869A1 (en) 2005-06-23
EA010291B1 (ru) 2008-08-29
KR20070009533A (ko) 2007-01-18
SG148215A1 (en) 2008-12-31
EP1706133A2 (en) 2006-10-04
CA2547869C (en) 2014-01-14
CN1913915B (zh) 2010-12-01
EA200601079A1 (ru) 2006-12-29
WO2005057218A2 (en) 2005-06-23
US11235028B2 (en) 2022-02-01
PL1706133T3 (pl) 2011-04-29
CN1913915A (zh) 2007-02-14
JP4750716B2 (ja) 2011-08-17
AU2004296828A1 (en) 2005-06-23
WO2005056042A2 (en) 2005-06-23
PT1706133E (pt) 2010-12-07
WO2005057218A3 (en) 2005-11-17
KR101287905B1 (ko) 2013-07-23
US20190381139A1 (en) 2019-12-19
DE602004029500D1 (de) 2010-11-18
DK1706133T3 (da) 2011-01-17
IL175974A (en) 2015-09-24
HK1102492A1 (en) 2007-11-23
IL175974A0 (en) 2006-10-05
WO2005056042A3 (en) 2005-11-10
EP1706133B1 (en) 2010-10-06
WO2005056055A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
UA83272C2 (uk) Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну
WO2006138238A3 (en) Methods of protecting against apoptosis using lipopeptides
EP1554290A4 (en) ANALOGUES AND PROMEDICAMENTS OF BUPRENORPHINE
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
IL163781A0 (en) Purine derivatives as kinase inhibitors
CL2003002770A1 (es) Compuestos derivados de pirrol e imiddazol; composiciones farmaceuticas que los contienen; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de enfermedades que estan asociadas con la modulacion de los receptores a canabinoides
SE0202241D0 (sv) Novel Compounds
IL163777A0 (en) Kinase inhibitors
TN2009000034A1 (en) Smac peptidomimetics useful as iap inhibitors
AU2002327180A1 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
UA83240C2 (uk) Інгібітори каспази, що містять ізоксазолінове кільце
NO20000832D0 (no) Fremgangsmåte for beskyttelse av undervannsinstallasjoner, samt anordning for gjennomføring av slik beskyttelse
UA88166C2 (uk) Застосування пептидних сполук для лікування есенційного тремтіння та інших синдромів тремтіння
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
DE60329326D1 (de) Tace inhibitoren
EA200870584A1 (ru) Пролекарства пенема
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
EP1605926A4 (en) USE OF PINITOL OR CHIROINOSITOL FOR THE PROTECTION OF THE LIVER
GB0401496D0 (en) The copy protection of optical discs
MY148435A (en) Methods of protecting against radiation using flagellin
ATE434680T1 (de) Infrarotbügeleisen
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer